DelveInsight’s ‘H. pylori Infection – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the H. pylori Infection, historical and forecasted epidemiology as well as the H. pylori Infection market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Helicobacter Pylori Infections Market Overview
Helicobacter pylori (H. pylori) infection is caused by bacteria, which in turn, causes stomach infection. These infections cause stomach and duodenum changes, leading to gastritis and stomach cancer. Consuming contaminated food and water (with fecal matter) spreads H. pylori infection. Patients harboring the bacteria are asymptomatic with abdominal pain, nausea, vomiting, and dyspepsia developing only after gastritis and peptic ulcer disease have set in. H. pylori is the most important cause for chronic or atrophic gastritis, peptic ulcer, gastric lymphoma, and gastric carcinoma; however, these complications are less often seen in children and adolescents than adults. H. pylori infection is usually acquired in early childhood and persists without treatment. Four important components lead to the formation of clinical diseases such as gastritis and ulcer in H. pylori infection. First, the urease activity of H. pylori plays an important role in countering the stomach’s acidic environment. Second, the flagella-mediated motility helps H. pylori bacterium move toward the host gastric epithelial cells. This is followed by the bacterial adhesins interacting with the host cell receptors, leading to successful colonization and persistent infection. Finally, many effector proteins/toxins include cytotoxin-associated gene A (Cag A) and vacuolating cytotoxin A (VacA) released by H. pylori, leading to host tissue damage.
Learn more about the Helicobacter Pylori Infections market @ Helicobacter Pylori Infections Market Landscape
Helicobacter Pylori Infections Epidemiological Segmentation
Helicobacter Pylori Infections incident cases
Helicobacter Pylori Infections treated cases
Helicobacter Pylori Infections diagnosed cases
Helicobacter Pylori Infections prevalent cases
Helicobacter Pylori Infections Market Outlook
With no single accurate diagnostic tool or method, the current diagnosis depends on both invasive and noninvasive methods. The treatment regime has seen many changes, with H. pylori designated as a Class I carcinogen by WHO and a Qualifying Pathogen under the US FDA GAIN Act. The first effective therapy for H. pylori was introduced in the 1980s; since then, there have been major changes. The current treatment regime for H. pylori is therapeutic and not prophylactic; the goal is to eradicate the bacteria, as eradication alone is paramount for healing associated peptic ulcers and preventing relapses. But the growing prevalence of antibiotic resistance has made it a global challenge.Most treatment guidelines recommend triple therapies, a combination of antibiotics with either antisecretories or PPIs or other acid-regulating agents, as the first line of treatment for eradicating H. pylori. Monotherapies prove ineffective as stomach acidity reduces the efficacy of antibiotics. Moreover, increasing antibiotic resistance has added to the troubles with only a few antibiotics active against H. pylori, including clarithromycin, amoxicillin, metronidazole, fluoroquinolone (levofloxacin, norfloxacin), tetracycline, and rifabutin.
Key Companies in the Helicobacter Pylori Infections Market Include
Phathom Pharmaceuticals
Redhill Biopharma
Takeda Pharmaceutical
Otsuka Pharmaceutical
Juvisé Pharmaceuticals
AbbVie
Cumberland Pharmaceuticals
Pernix Therapeutics
Eisai Co
And many others
Helicobacter Pylori Infections Therapies Covered and Analyzed in the Report Market Include:
VOQUEZNA TRIPLE PAK
TALICIA (RHB-105)
BAS 118, SCG321,
R435/R529
Lansoprazole
Esomeprazole
OBMT
Tegoprazan
GT08
Learn more about the Helicobacter Pylori Infections Market, Key Companies, and Emerging Therapies
Table of Contents
Key Insights
Helicobacter Pylori Infections Report Introduction
Executive Summary of the Helicobacter Pylori Infections Market
Helicobacter Pylori Infections Disease Background and Overview
Helicobacter Pylori Infections Epidemiology and patient population
Helicobacter Pylori Infections Market Emerging Therapies
Helicobacter Pylori Infections Market Drivers
Helicobacter Pylori Infections Market Barriers
Market Access and Reimbursement of Therapies
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Learn more about the detailed report offerings @ Helicobacter Pylori Infections Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services